Commission Taking ‘Due Account’ Of Scathing Report On EU Clinical Trial Bottlenecks

Following publication of a report by the European Federation of Pharmaceutical Industry Associations (EFPIA) in which EFPIA concluded that the EU was becoming a less attractive location for conducting clinical research, the European Commission has told the Pink Sheet that it had heard the concerns raised by stakeholders regarding bottlenecks and regulatory insufficiencies that contribute to a decline in the number of clinical trials conducted in Europe. In its response, the European Commission mentions a number of proposed actions. It is unclear, however, how far the actions proposed will address these concerns.